Nearly 20 percent of people in the United States suffer from peptic-acid disorders such as chronic heartburn. When the first proton pump inhibitor(PPI) medication received approval in 1989, many patients with persistent heartburn—as well as other conditions such as peptic ulcer disease (PUD), nonsteroidal anti-inflammatory drug-induced gastropathy, and gastroesophageal reflux disease (GERD)—thought they'd finally found relief. […]
Based in Kalamazoo, Michigan, the Stryker Corporation is one of the largest medical equipment and orthopedic device manufacturers in the world. Some of the company's most popular offerings are various hip replacement systems, designed to be more durable and provide younger, more active patients with a greater range of motion. However, not all hip replacement […]
Pradaxa is an anticoagulant medication that offers patients greater convenience, compared to older blood-thinners, such as warfarin. The drug received approval from the Food and Drug Administration (FDA) in 2010 and in the years since, has become one of the most prescribed drugs in its class. While Pradaxa proves effective in preventing blood clots and strokes […]
Benicar is a popular angiotensin II receptor antagonist drug used to treat high blood pressure and hypertension. Developed by Japanese pharmaceutical company Daiichi Sankyo and marketed in the United States by Forest Laboratories, Benicar is prescribed to more than 11 million patients each year. While the drug has been shown to successfully lower blood pressure, […]
DePuy Orthopaedics's popular ASR Hip Resurfacing System® and ASR XL Acetabular System® devices were implanted in more than 93,000 patients worldwide before the company recalled them due to an abnormally high rate of failure. If you had your hip resurfaced or replaced between 2005 and 2010, learning the signs and symptoms of a failing DePuy hip […]
Stryker is a leading medical technologies firm known in part for its extensive line of hip replacement systems. However, in recent years, complaints about flaws in the company's metal-on-metal designs have led to recalls of several Stryker hip replacement devices, including the Rejuvenate® and ABG II®. In this article, we outline information about affected Stryker implants and […]
Women are more likely than men to suffer hair loss from Taxotere® simply because they're more likely to be diagnosed with breast cancer. Taxotere (docetaxel) is a popular chemotherapy treatment for this disease. Hair loss, also known as alopecia, is a common side effect of chemotherapy. Most patients can expect their hair to grow back within […]
Am I Eligible For A Taxotere® Hair Loss Settlement? Patients are often warned about the potential for hair loss before starting a course of cancer treatment. Sanofi-Aventis states in its Taxotere® clinical trial information that most patients on the drug experience the side effect of hair loss during treatment, but that hair generally grows back […]
While some batches of Taxotere® have been recalled, the drug is still on the market and regularly used in chemotherapy treatments. There have been at least two widespread recalls of the medication, including: April 2016. Drugmaker Sanofi-Aventis recalled several batches of Taxotere in the United Kingdom due to a manufacturing error. According to the company, a software […]
Many women who have been diagnosed with early-stage breast cancer (EBC) receive a mixture (or cocktail) of drugs during chemotherapy sessions. As a result, it can be difficult for a patient to know whether she was given Taxotere®, how often she received the drug, and how much was administered. You may have received Taxotere during chemotherapy […]